Want to Strengthen American Democracy? The Science of Collaboration Can Help
The science of collaboration explores why diverse individuals choose to work together and how to design systems that encourage successful collaborations.
This article is part of the magazine, "The Future of Science In America: The Election Issue," co-published by LeapsMag, the Aspen Institute Science & Society Program, and GOOD.
American politics has no shortage of ailments. Many do not feel like their voice matters amid the money and influence amassed by corporations and wealthy donors. Many doubt whether elected officials and bureaucrats can or even want to effectively solve problems and respond to citizens' needs. Many feel divided both physically and psychologically, and uncomfortable (if not scared) at the prospect of building new connections across lines of difference.
Strengthening American democracy requires countering these trends. New collaborations between university researchers and community leaders such as elected officials, organizers, and nonprofit directors can help. These collaborations can entail everything from informal exchanges to co-led projects.
But there's a catch. They require that people with diverse forms of knowledge and lived experience, who are often strangers, choose to engage with one another. We know that strangers often remain strangers.
That's why a science of collaboration that centers the inception question is vital: When do diverse individuals choose to work together in the first place? How can we design institutions that encourage beneficial collaborations to arise and thrive? And what outcomes can occur?
How Collaborations Between Researchers and Community Leaders Can Help
First consider the feeling of powerlessness. Individual action becomes more powerful when part of a collective. For ordinary citizens, voting and organizing are arguably the two most impactful forms of collective action, and as it turns out there is substantial research on how to increase turnout and how to build powerful civic associations. Collaborations between researchers familiar with that work and organizers and nonprofit leaders familiar with a community's context can be especially impactful.
For example, in 2019, climate organizers with a nonpartisan group in North Carolina worked with a researcher who studies organizing to figure out how to increase volunteer commitment—that is, how to transform volunteers who only attend meetings into leaders who take responsibility for organizing others. Together, they designed strategies that made sense for the local area. Once implemented, these strategies led to a 161% year-over-year increase in commitment. More concretely, dozens of newly empowered volunteers led events to raise awareness of how climate change was impacting the local community and developed relationships with local officials and business owners, all while coming to see themselves as civic leaders. This experience also fed back into the researcher's work, motivating the design of future studies.
Or consider how researchers and local elected officials can collaborate and respond to novel challenges like the coronavirus. For instance, in March 2020, one county in Upstate New York suddenly had to figure out how to provide vital services like internet and health screenings for residents who could no longer visit shuttered county offices. They turned to a researcher who knew about research on mobile vans. Together, they spoke about the benefits and costs of mobile vans in general, and then segued into a more specific conversation about what routings and services would make sense in this specific locale. Their collaboration entailed a few conversations leading up to the county's decision, and in the end the county received helpful information and the researcher learned about new implementation challenges associated with mobile vans.
In April, legislators in another Upstate New York county realized they needed honest, if biting, feedback from local mayors about their response to the pandemic. They collaborated with researchers familiar with survey methodology. County legislators supplied the goals and historical information about fraught county–city relationships, while researchers supplied evidence-based techniques for conducting interviews in delicate contexts. These interviews ultimately revealed mayors' demand for more up-to-date coronavirus information from the county and also more county-led advocacy at the state level.
To be sure, there are many situations in which elected officials' lack of information is not the main hurdle. Rather, they need an incentive to act. Yet this is another situation in which collaborations between university researchers and community leaders focused on evidence-based, context-appropriate approaches to organizing and voter mobilization could produce needed pressure.
This brings me to the third way in which collaborations between researchers and community leaders can strengthen American democracy. They entail diverse people working to develop a common interest by building new connections across lines of difference. This is a core democratic skill that withers in the absence of practice.
In addition to credibility, we've learned that potential collaborators also care about whether others will be responsive to their goals and constraints, understand their point of view, and will be enjoyable to interact with.
The Science of Collaboration
The previous examples have one thing in common: a collaboration actually took place.
Yet that often does not happen. While there are many reasons why collaborations between diverse people should arise we know far less about when they actually do arise.
This is why a science of collaboration centered on inception is essential. Some studies have already revealed new insights. One thing we've learned is that credibility is important, but often not enough. By credibility, I mean that people are more likely to collaborate when they perceive each other to be trustworthy and have useful information or skills to share. Potential collaborators can signal their credibility by, for instance, identifying shared values and mentioning relevant previous experiences. One study finds that policymakers are more interested in collaborating with researchers who will share findings that are timely and locally relevant—that is, the kind that are most useful to them.
In addition to credibility, we've learned that potential collaborators also care about whether others will be responsive to their goals and constraints, understand their point of view, and will be enjoyable to interact with. For instance, potential collaborators can explicitly acknowledge that they know the other person is busy, or start with a question rather than a statement to indicate being interested. One study finds that busy nonprofit leaders are more likely to collaborate with researchers who explicitly state that (a) they are interested in learning about the leaders' expertise, and (b) they will efficiently share what they know. Another study underscores that potential collaborators need to feel like they know how to interact—that is, to feel like they have a "script" for what's appropriate to say during the interaction.
We're also learning that institutions (such as matchmaking organizations) can reduce uncertainty about credibility and relationality, and also help collaborations start off on the right foot. They are a critical avenue for connecting strangers. For instance, brokers can use techniques that increase the likelihood that diverse people feel comfortable sharing what they know, raising concerns, and being responsive to others.
Looking Ahead
A science of collaboration that centers the inception question is helpful on two levels. First, it provides an evidence base for how to effectively connect diverse people to work together. Second, when applied to university researchers and community leaders, it can produce collaborations that strengthen American democracy. Moreover, these collaborations are easily implemented, especially when informal and beginning as a conversation or two (as in the mobile vans example).
Existing research on the science of collaboration has already yielded actionable insights, yet we still have much to learn. For instance, we need to better understand the latent demand. Interviews that ask a wide variety of community leaders and researchers who have not previously collaborated to talk about why doing so might be helpful would be enlightening. They could also be a useful antidote to the narrative of conflict that often permeates discussions about the role of science in American politics.
In addition, we need to learn more about the downstream consequences of these collaborations, such as whether new networks arise that include colleagues of the initial collaborators. Here, it would be helpful to study the work of brokers – how they introduce people to each other, how much they follow up, and the impact of those decisions.
Ultimately, expanding the evidence base of the science of collaboration, and then directly applying what we learn, will provide important new and actionable avenues for strengthening American democracy.
[Editor's Note: To read other articles in this special magazine issue, visit the beautifully designed e-reader version.]
A company uses AI to fight muscle loss and unhealthy aging
In December 2022, a company called BioAge Labs published findings on a drug that worked to prevent muscular atrophy, or the loss of muscle strength and mass, in older people.
There’s a growing need to slow down the aging process. The world’s population is getting older and, according to one estimate, 80 million Americans will be 65 or older by 2040. As we age, the risk of many chronic diseases goes up, from cancer to heart disease to Alzheimer’s.
BioAge Labs, a company based in California, is using genetic data to help people stay healthy for longer. CEO Kristen Fortney was inspired by the genetics of people who live long lives and resist many age-related diseases. In 2015, she started BioAge to study them and develop drug therapies based on the company’s learnings.
The team works with special biobanks that have been collecting blood samples and health data from individuals for up to 45 years. Using artificial intelligence, BioAge is able to find the distinctive molecular features that distinguish those who have healthy longevity from those who don’t.
In December 2022, BioAge published findings on a drug that worked to prevent muscular atrophy, or the loss of muscle strength and mass, in older people. Much of the research on aging has been in worms and mice, but BioAge is focused on human data, Fortney says. “This boosts our chances of developing drugs that will be safe and effective in human patients.”
How it works
With assistance from AI, BioAge measures more than 100,000 molecules in each blood sample, looking at proteins, RNA and metabolites, or small molecules that are produced through chemical processes. The company uses many techniques to identify these molecules, some of which convert the molecules into charged atoms and then separating them according to their weight and charge. The resulting data is very complex, with many thousands of data points from patients being followed over the decades.
BioAge validates its targets by examining whether a pathway going awry is actually linked to the development of diseases, based on the company’s analysis of biobank health records and blood samples. The team uses AI and machine learning to identify these pathways, and the key proteins in the unhealthy pathways become their main drug targets. “The approach taken by BioAge is an excellent example of how we can harness the power of big data and advances in AI technology to identify new drugs and therapeutic targets,” says Lorna Harries, a professor of molecular genetics at the University of Exeter Medical School.
Martin Borch Jensen is the founder of Gordian Biotechnology, a company focused on using gene therapy to treat aging. He says BioAge’s use of AI allows them to speed up the process of finding promising drug candidates. However, it remains a challenge to separate pathologies from aspects of the natural aging process that aren’t necessarily bad. “Some of the changes are likely protective responses to things going wrong,” Jensen says. “Their data doesn’t…distinguish that so they’ll need to validate and be clever.”
Developing a drug for muscle loss
BioAge decided to focus on muscular atrophy because it affects many elderly people, making it difficult to perform everyday activities and increasing the risk of falls. Using the biobank samples, the team modeled different pathways that looked like they could improve muscle health. They found that people who had faster walking speeds, better grip strength and lived longer had higher levels of a protein called apelin.
Apelin is a peptide, or a small protein, that circulates in the blood. It is involved in the process by which exercise increases and preserves muscle mass. BioAge wondered if they could prevent muscular atrophy by increasing the amount of signaling in the apelin pathway. Instead of the long process of designing a drug, they decided to repurpose an existing drug made by another biotech company. This company, called Amgen, had explored the drug as a way to treat heart failure. It didn’t end up working for that purpose, but BioAge took note that the drug did seem to activate the apelin pathway.
BioAge tested its new, repurposed drug, BGE-105, and, in a phase 1 clinical trial, it protected subjects from getting muscular atrophy compared to a placebo group that didn’t receive the drug. Healthy volunteers over age 65 received infusions of the drug during 10 days spent in bed, as if they were on bed rest while recovering from an illness or injury; the elderly are especially vulnerable to muscle loss in this situation. The 11 people taking BGE-105 showed a 100 percent improvement in thigh circumference compared to 10 people taking the placebo. Ultrasound observations also revealed that the group taking the durg had enhanced muscle quality and a 73 percent increase in muscle thickness. One volunteer taking BGE-105 did have muscle loss compared to the the placebo group.
Heather Whitson, the director of the Duke University Centre for the study of aging and human development, says that, overall, the results are encouraging. “The clinical findings so far support the premise that AI can help us sort through enormous amounts of data and identify the most promising points for beneficial interventions.”
More studies are needed to find out which patients benefit the most and whether there are side effects. “I think further studies will answer more questions,” Whitson says, noting that BGE-105 was designed to enhance only one aspect of physiology associated with exercise, muscle strength. But exercise itself has many other benefits on mood, sleep, bones and glucose metabolism. “We don’t know whether BGE-105 will impact these other outcomes,” she says.
The future
BioAge is planning phase 2 trials for muscular atrophy in patients with obesity and those who have been hospitalized in an intensive care unit. Using the data from biobanks, they’ve also developed another drug, BGE-100, to treat chronic inflammation in the brain, a condition that can worsen with age and contributes to neurodegenerative diseases. The team is currently testing the drug in animals to assess its effects and find the right dose.
BioAge envisions that its drugs will have broader implications for health than treating any one specific disease. “Ultimately, we hope to pioneer a paradigm shift in healthcare, from treatment to prevention, by targeting the root causes of aging itself,” Fortney says. “We foresee a future where healthy longevity is within reach for all.”
How old fishing nets turn into chairs, car mats and Prada bags
A company called Aquafil is turning the fibers from fishing nets and old carpets into new threads for chairs, car mats, bikinis and Prada bags.
Discarded nylon fishing nets in the oceans are among the most harmful forms of plastic pollution. Every year, about 640,000 tons of fishing gear are left in our oceans and other water bodies to turn into death traps for marine life. London-based non-profit World Animal Protection estimates that entanglement in this “ghost gear” kills at least 136,000 seals, sea lions and large whales every year. Experts are challenged to estimate how many birds, turtles, fish and other species meet the same fate because the numbers are so high.
Since 2009, Giulio Bonazzi, the son of a small textile producer in northern Italy, has been working on a solution: an efficient recycling process for nylon. As CEO and chairman of a company called Aquafil, Bonazzi is turning the fibers from fishing nets – and old carpets – into new threads for car mats, Adidas bikinis, environmentally friendly carpets and Prada bags.
For Bonazzi, shifting to recycled nylon was a question of survival for the family business. His parents founded a textile company in 1959 in a garage in Verona, Italy. Fifteen years later, they started Aquafil to produce nylon for making raincoats, an enterprise that led to factories on three continents. But before the turn of the century, cheap products from Asia flooded the market and destroyed Europe’s textile production. When Bonazzi had finished his business studies and prepared to take over the family company, he wondered how he could produce nylon, which is usually produced from petrochemicals, in a way that was both successful and ecologically sustainable.
The question led him on an intellectual journey as he read influential books by activists such as world-renowned marine biologist Sylvia Earle and got to know Michael Braungart, who helped develop the Cradle-to-Cradle ethos of a circular economy. But the challenges of applying these ideologies to his family business were steep. Although fishing nets have become a mainstay of environmental fashion ads—and giants like Dupont and BASF have made breakthroughs in recycling nylon—no one had been able to scale up these efforts.
For ten years, Bonazzi tinkered with ideas for a proprietary recycling process. “It’s incredibly difficult because these products are not made to be recycled,” Bonazzi says. One complication is the variety of materials used in older carpets. “They are made to be beautiful, to last, to be useful. We vastly underestimated the difficulty when we started.”
Soon it became clear to Bonazzi that he needed to change the entire production process. He found a way to disintegrate old fibers with heat and pull new strings from the discarded fishing nets and carpets. In 2022, his company Aquafil produced more than 45,000 tons of Econyl, which is 100% recycled nylon, from discarded waste.
More than half of Aquafil’s recyclate is from used goods. According to the company, the recycling saves 90 percent of the CO2 emissions compared to the production of conventional nylon. That amounts to saving 57,100 tons of CO2 equivalents for every 10,000 tons of Econyl produced.
Bonazzi collects fishing nets from all over the world, including Norway and Chile—which have the world’s largest salmon productions—in addition to the Mediterranean, Turkey, India, Japan, Thailand, the Philippines, Pakistan, and New Zealand. He counts the government leadership of Seychelles as his most recent client; the island has prohibited ships from throwing away their fishing nets, creating the demand for a reliable recycler. With nearly 3,000 employees, Aquafil operates almost 40 collection and production sites in a dozen countries, including four collection sites for old carpets in the U.S., located in California and Arizona.
First, the dirty nets are gathered, washed and dried. Bonazzi explains that nets often have been treated with antifouling agents such as copper oxide. “We recycle the coating separately,” he says via Zoom from his home near Verona. “Copper oxide is a useful substance, why throw it away?”
Still, only a small percentage of Aquafil’s products are made from nets fished out of the ocean, so your new bikini may not have saved a strangled baby dolphin. “Generally, nylon recycling is a good idea,” says Christian Schiller, the CEO of Cirplus, the largest global marketplace for recyclates and plastic waste. “But contrary to what consumers think, people rarely go out to the ocean to collect ghost nets. Most are old, discarded nets collected on land. There’s nothing wrong with this, but I find it a tad misleading to label the final products as made from ‘ocean plastic,’ prompting consumers to think they’re helping to clean the oceans by buying these products.”
Aquafil gets most of its nets from aqua farms. Surprisingly, one of Aquafil’s biggest problems is finding enough waste. “I know, it’s hard to believe because waste is everywhere,” Bonazzi says. “But we need to find it in reliable quantity and quality.” He has invested millions in establishing reliable logistics to source the fishing nets. Then the nets get shredded into granules that can be turned into car mats for the new Hyundai Ioniq 5 or a Gucci swimsuit.
The process works similarly with carpets. In the U.S. alone, 3.5 billion pounds of carpet are discarded in landfills every year, and less than 3 percent are currently recycled. Aquafil has built a recycling plant in Phoenix to help divert 12,500 tons of carpets from the landfill every year. The carpets are shredded and deconstructed into three components: fillers such as calcium carbonate will be reused in the cement industry, synthetic fibers like polypropylene can be used for engineering plastics, and nylon. Only the pelletized nylon gets shipped back to Europe for the production of Econyl. “We ship only what’s necessary,” Bonazzi says. Nearly 50 percent of his nylon in Italy and Slovenia is produced from recyclate, and he hopes to increase the percentage to two-thirds in the next two years.
His clients include Interface, the leading world pioneer for sustainable flooring, and many other carpet producers plus more than 2500 fashion labels, including Gucci, Prada, Patagonia, Louis Vuitton, Adidas and Stella McCartney. “Stella McCartney just introduced a parka that’s made 100 percent from Econyl,” Bonazzi says. “We’re also in a lot of sportswear because Nylon is a good fabric for swimwear and for yoga clothes.” Next, he’s looking into sunglasses and chairs made with Econyl - for instance, the flexible ergonomic noho chair, designed by New Zealand company Formway.
“When I look at a landfill, I see a gold mine," Bonazzi says.
“Bonazzi decided many years ago to invest in the production of recycled nylon though industry giants halted similar plans after losing large investments,” says Anika Herrmann, vice president of the German Greentech-competitor Camm Solutions, which creates bio-based polymers from cane sugar and other ag waste. “We need role models like Bonazzi who create sustainable solutions with courage and a pioneering spirit. Like Aquafil, we count on strategic partnerships to enable fast upscaling along the entire production chain.”
Bonazzi’s recycled nylon is still five to 10 percent more expensive than conventionally produced material. However, brands are increasingly bending to the pressure of eco-conscious consumers who demand sustainable fashion. What helped Bonazzi was the recent rise of oil prices and the pressure on industries to reduce their carbon footprint. Now Bonazzi says, “When I look at a landfill, I see a gold mine.”
Ideally, the manufacturers take the products back when the client is done with it, and because the nylon can theoretically be reused nearly infinitely, the chair or bikini could be made into another chair or bikini. “But honestly,” Bonazzi half-jokes, “if someone returns a McCartney parka to me, I’ll just resell it because it’s so expensive.”
The next step: Bonazzi wants to reshape the entire nylon industry by pivoting from post-consumer nylon to plant-based nylon. In 2017, he began producing “nylon-6,” together with Genomatica in San Diego. The process uses sugar instead of petroleum. “The idea is to make the very same molecule from sugar, not from oil,” he says. The demonstration plant in Ljubljana, Slovenia, has already produced several hundred tons of nylon, and Genomatica is collaborating with Lululemon to produce plant-based yoga wear.
Bonazzi acknowledges that his company needs a few more years before the technology is ready to meet his ultimate goal, producing only recyclable products with no petrochemicals, low emissions and zero waste on an industrial scale. “Recycling is not enough,” he says. “You also need to produce the primary material in a sustainable way, with a low carbon footprint.”